Drugs / TTAX03
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06236308 | Jul 2024 → Jan 2025 | — | BioTissue Holdings, Inc | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06780306 | Dec 2024 → Jan 2026 | dry eye syndrome | BioTissue Holdings, Inc | Completed | No outcome recorded |
| Phase 2 | NCT05079035 | Dec 2021 → Mar 2025 | osteoarthritis, knee | BioTissue Holdings, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTAX03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05079035 ↗ |
| Modality | Other / unclassified | “TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product” NCT06236308 ↗ |
| Route | Other | “Each subject will receive a single IA injection into the knee under local anesthesia” NCT05079035 ↗ |